In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
|Articles|September 11, 2017
The Mechanisms of Abuse-Deterrent Opioids
In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the mechanisms by which abuse-deterrent opioids prevent misuse.
Advertisement
In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the mechanisms by which abuse-deterrent opioids prevent misuse.
Advertisement
Related to this article
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
3
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
4
Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer
5